MedTrace Logo

Treating Anorectal Dysfunction in MS

NCT02609607 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-01-22

Study results available
· View outcomes & findings →

Summary

The investigators seek to test whether incorporating the scheduled dosing of a bisacodyl 10 mg rectal suppository every other day improves bowel-related symptoms in patients with multiple sclerosis. Patients will be randomized to receive either a placebo suppository or bisacodyl suppository dosed every other day for 4 weeks.

Conditions

Interventions

DRUG

Bisacodyl

Rectal suppository

OTHER

Placebo

Rectal suppository

Sponsors & Collaborators

  • Consortium of Multiple Sclerosis Centers

    collaborator OTHER

  • David Levinthal

    lead OTHER

Principal Investigators

  • David J Levinthal, MD, PhD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-11-30
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02609607 on ClinicalTrials.gov